William Blair & Company, LLC.
Exhibit 1
ARIAD Pharmaceuticals, Inc.
Sum-of-Parts Fair Value
(dollars in thousands)
Stage of Estimated Probability of Percentage of Probability. Value Percentage of
Drug Peak Sales
Development Launch Date Commercialization Sales to Company Adjusted NPV per Share Fair Value
Iclusig-CML January 2013/
9746.822 Marketed 100% 100% $1,843,975 $9.85 83.4%
Worldwide July 2013
AP28113—ALK* NSCLC
S280918 Phase IflI 1-122016 81% 100% $325,268 $1.74 14.7%
Worldwide
Subtotal $2,189,243 $11.59 98.2%
Net Cash at Yearend 2014 $63,406 $0.34 2.9%
Net Present Value of additional Gain (Loss)' ($22,727) ($0.12) (1.0%)
Sum-of-Parts Fair Value $2,209,922 $11.81 100.0%
- Includes costs nal *Golly reined to programs above
Sources. Company reports and %ma'am Emir 8 Company. L L.C. estimates
5 I Y. Katherine Xu, Ph.D.
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0106554
CONFIDENTIAL SDNY_GM_00252738
EFTA01450729